In patients with type 1 diabetes, long duration of the disease and poor glycemic control increase the risk for micro- and macrovascular complications. A significant proportion of type 1 diabetic patients who develop these complications exhibit clinical features commonly seen in subjects with the metabolic syndrome (MetS), including dyslipidemia, insulin resistance, obesity, hypertension, and chronic inflammation ([@B1],[@B2]). Vascular diseases are also common in patients with IgA glomerulonephritis (IgAGN), and those with a progressive form of the disease run a significantly elevated risk of developing different cardiovascular sequela ([@B3]). Whether the MetS is independently associated with the progression of IgAGN is currently unclear, but at least several related factors, including hyperuricemia, hypertriglyceridemia, weight, insulin resistance, and inflammation, seem to associate with the development of kidney dysfunction in IgAGN ([@B4],[@B5]).

Many of these clinical subphenotypes likely emerge from the complex interactions between a genetic background, lifestyle, and environmental factors. Recent studies have highlighted the role of the innate immune system in the developmental process of these metabolic abnormalities ([@B6]). Our living environment is inhabited with commensal and pathogenic bacteria, which have both beneficial and detrimental effects on human health. If the immune defense functions properly, these microorganisms rarely cause any serious infections in healthy individuals. The situation is different in immunocompromised patients---local infections, use of antibiotics, and even diet may lead to the colonization of opportunistic bacteria in various sites of the body. In diabetic patients, long duration of the disease and poor glycemic control increase the risk for urinary tract, pulmonary, oral, and skin infections ([@B6],[@B7]).

Lipopolysaccharides (LPS) are unique glycolipids in the cell wall of gram-negative bacteria. LPS molecules, also known as bacterial endotoxins, may trigger acute and chronic inflammation, leading to immune cell activation and cytokine release. HDL cholesterol is one of the most important factors involved in the elimination of LPS molecules from circulation. In healthy subjects, LPS is mainly bound to HDL, whereas in patients with sepsis, LPS is redistributed toward LDL and VLDL lipoproteins ([@B8]). High LPS activity combined with low HDL levels increases the risk for cardiovascular disease ([@B9]).

LPS infusion in mammals leads to the appearance of factors known to be associated with the MetS: elevated levels of proinflammatory markers, dyslipidemia, fasting hyperglycemia, insulin resistance, and obesity ([@B10]--[@B12]). In some research applications, bacterial endotoxins have been used to induce acute kidney injury in animals. Monocyte chemoattractant protein-1 (MCP1) is a potential marker for progressive renal disease because its expression and excretion are also regulated by bacterial endotoxins ([@B13],[@B14]).

We have recently shown that high serum levels of LPS activity are associated with the development and progression of kidney disease in Finnish type 1 diabetic patients. Most of the patients with high serum LPS activity exhibited features of dyslipidemia and insulin resistance ([@B15]). These metabolic abnormalities are frequently observed in diabetic patients with micro- or macrovascular complications ([@B2]). To our knowledge, no previous studies have explored the potential links between bacterial endotoxins and the MetS in subjects with impaired kidney function. Therefore, we wanted to investigate whether serum LPS activity is associated with metabolic risk factors in three distinct study populations: type 1 diabetic patients with various degrees of kidney disease, patients with IgAGN, and nondiabetic subjects.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Finnish Diabetic Nephropathy Study {#s6}
----------------------------------

A total of 911 patients with type 1 diabetes and 225 nondiabetic control (NDC) subjects were selected from the Finnish Diabetic Nephropathy Study (FinnDiane). In contrast to our previous baseline study ([@B15]), all blood samples and clinical measurements were obtained from diabetic patients during their prospective visit. Type 1 diabetes was defined as an onset of diabetes before the age of 40 years and permanent insulin treatment initiated within 1 year of diagnosis. The diabetic patients were divided into three groups by albumin excretion rate (AER) in two of three urine collections: 594 with normal AER (\<30 mg/24 h), 144 with microalbuminuria (30--300 mg/24 h), and 173 with macroalbuminuria (≥300 mg/24 h; [Table 1](#T1){ref-type="table"}). The NDC subjects from the FinnDiane study were divided into two groups by absence or presence of overweight, defined as a BMI cutoff of 25 kg/m^2^ (see [[Data analysis and Statistical methods]{.smallcaps}](#s13){ref-type="sec"}).

###### 

Clinical characteristics of type 1 diabetic patients

  Variable                       Normal AER          Microalbuminuria                                   Macroalbuminuria
  ------------------------------ ------------------- -------------------------------------------------- ---------------------------------------------------
  *N* (male/female)              587 (257/330)       144 (65/79)                                        173 (110/63)[\*](#t1n1){ref-type="table-fn"}
  Age (years)                    44 (36--53)         46 (37--55)                                        48 (40--56)[†](#t1n2){ref-type="table-fn"}
  Age at onset (years)           17 (10--25)         11 (6--19)[\*](#t1n1){ref-type="table-fn"}         11 (7--16)[\*](#t1n1){ref-type="table-fn"}
  Duration of diabetes (years)   28 ± 12             33 ± 11[\*](#t1n1){ref-type="table-fn"}            35 ± 9[\*](#t1n1){ref-type="table-fn"}
  HbA~1c~ (%)                    7.7 ± 1.3           7.8 ± 1.8                                          7.8 ± 2.0
  BMI (kg/m^2^)                  25.6 ± 4.2          26.4 ± 4.2[†](#t1n2){ref-type="table-fn"}          27.0 ± 4.9[\*](#t1n1){ref-type="table-fn"}
  Blood pressure (mmHg)                                                                                 
   Systolic                      136 ± 17            141 ± 19[†](#t1n2){ref-type="table-fn"}            146 ± 18[\*](#t1n1){ref-type="table-fn"}
   Diastolic                     78 ± 9              78 ± 10                                            80 ± 11[†](#t1n2){ref-type="table-fn"}
  Cholesterol (mmol/L)           4.7 ± 0.8           4.9 ± 0.8[†](#t1n2){ref-type="table-fn"}           4.8 ± 1.1
  Triglycerides (mmol/L)         0.90 (0.69--1.21)   0.95 (0.72--1.51)[†](#t1n2){ref-type="table-fn"}   1.35 (0.93--2.03)[\*](#t1n1){ref-type="table-fn"}
  HDL cholesterol (mmol/L)                                                                              
   Male                          1.5 ± 0.4           1.4 ± 0.4                                          1.3 ± 0.4[†](#t1n2){ref-type="table-fn"}
   Female                        1.7 ± 0.4           1.8 ± 0.5[†](#t1n2){ref-type="table-fn"}           1.5 ± 0.4[\*](#t1n1){ref-type="table-fn"}
  apoA1 (mg/dL)                  146 ± 32            152 ± 34                                           143 ± 33
  apoB (mg/dL)                   75 ± 19             78 ± 18                                            85 ± 25[\*](#t1n1){ref-type="table-fn"}
  LPS (EU/mL)                    57 (50--69)         56 (47--72)                                        67 (52--96)[\*](#t1n1){ref-type="table-fn"}
  LPS/HDL ratio                  37 (29--50)         35 (27--52)                                        50 (34--77)[\*](#t1n1){ref-type="table-fn"}
  CRP (mg/L)                     1.0 (0.3--2.5)      1.0 (0.5--2.5)                                     1.1 (0.6--2.9)
  eGFR (mL/min/1.73 m^2^)        102 (90--111)       96 (81--108)[\*](#t1n1){ref-type="table-fn"}       57 (35--84)[\*](#t1n1){ref-type="table-fn"}
  Medication (%)                                                                                        
   Lipid-lowering                22                  35[\*](#t1n1){ref-type="table-fn"}                 56[\*](#t1n1){ref-type="table-fn"}
   Antihypertensive              31                  79[\*](#t1n1){ref-type="table-fn"}                 98[\*](#t1n1){ref-type="table-fn"}
  Smoking (%)                    17                  20                                                 26[\*](#t1n1){ref-type="table-fn"}
  Retinopathy (%)                20                  55[\*](#t1n1){ref-type="table-fn"}                 78[\*](#t1n1){ref-type="table-fn"}
  Coronary heart disease (%)     6                   9                                                  15[\*](#t1n1){ref-type="table-fn"}

Continuous data are presented as the median (interquartile range) or as mean ± SD.

All variables are compared with normoalbuminuric patients:

\**P* ≤ 0.001,

†*P* ≤ 0.05.

IgAGN study {#s7}
-----------

The cohort with IgAGN was investigated in the Department of Internal Medicine in Tampere University Hospital (Tampere, Finland) and consisted of 223 patients living in the Pirkanmaa Health District in Finland (total population ∼440,000) who had been diagnosed with the disease during an 11-year period (1980--1990). IgAGN was defined as a glomerulonephritis with IgA as the sole or main glomerular immunofluorescence finding in a renal biopsy specimen. A total of 98 patients without diabetes were reinvestigated after a median (interquartile range \[IQR\]) of 16.5 (14--20) years from the original renal biopsy ([Table 2](#T2){ref-type="table"}). The median age during the prospective visit was 51 (41--62) years. The median for the estimated glomerular filtration rate (eGFR) was 72 (13--128) mL/min/1.73 m^2^ ([@B16]), and 26.5% of the patients presented with eGFR \<60 mL/min/1.73 m^2^. The median amount of proteinuria was 0.17 (0.1--0.52) g.

###### 

Clinical characteristics of nondiabetic study subjects

  Variable                   NDC-lean         NDC-ow                                            NDC-all          IgAGN
  -------------------------- ---------------- ------------------------------------------------- ---------------- -------------------------------------------------
  *N* (male/female)          219 (96/123)     126 (81/45)[\*](#t2n1){ref-type="table-fn"}       345 (177/168)    98 (61/37)
  Age (years)                33 ± 10          33 ± 9                                            33 ± 10          52 ± 13[\*](#t2n1){ref-type="table-fn"}
  BMI (kg/m^2^)              22.2 ± 1.7       28.2 ± 2.8[\*](#t2n1){ref-type="table-fn"}        24.3 ± 3.6       26.5 ± 4.3[\*](#t2n1){ref-type="table-fn"}
  Waist (cm)                                                                                                     
   Male                      85 (80--88)      97 (92--102)[†](#t2n2){ref-type="table-fn"}       89 (84--96)      91 (87--100)
   Female                    76 (72--81)      90 (86--98)[\*](#t2n1){ref-type="table-fn"}       79 (74--85)      80 (71--87)
  Blood pressure (mmHg)                                                                                          
   Systolic                  123 ± 14         130 ± 13[\*](#t2n1){ref-type="table-fn"}          126 ± 14         148 ± 21[\*](#t2n1){ref-type="table-fn"}
   Diastolic                 75 ± 8           80 ± 8                                            77 ± 8           90 ± 11[\*](#t2n1){ref-type="table-fn"}
  Glucose (mmol/L)           4.8 (4.5--5.1)   5.0 (4.7--5.4)[\*](#t2n1){ref-type="table-fn"}    4.9 (4.6--5.2)   4.7 (4.4--5.1)[†](#t2n2){ref-type="table-fn"}
  Insulin (μU/mL)            4.2 (2.9--5.5)   5.7 (4.4--10.0)[\*](#t2n1){ref-type="table-fn"}   4.8 (3.3--6.7)   7.7 (6.1--10.7)[\*](#t2n1){ref-type="table-fn"}
  HOMA-IR                    1.0 (0.8--1.5)   1.3 (0.8--2.0)[†](#t2n2){ref-type="table-fn"}     1.1 (0.8--1.6)   1.6 (1.1--2.2)[\*](#t2n1){ref-type="table-fn"}
  Cholesterol (mmol/L)       4.5 ± 0.9        4.9 ± 0.9[\*](#t2n1){ref-type="table-fn"}         4.7 ± 0.9        5.3 ± 1.1[\*](#t2n1){ref-type="table-fn"}
  Triglycerides (mmol/L)     0.8 (0.7--1.1)   1.1 (0.8--1.4)                                    0.9 (0.7--1.2)   1.2 (0.8--1.6)[\*](#t2n1){ref-type="table-fn"}
  HDL cholesterol (mmol/L)                                                                                       
   Male                      1.5 ± 0.3        1.4 ± 0.3[†](#t2n2){ref-type="table-fn"}          1.4 ± 0.3        1.3 ± 0.3[†](#t2n2){ref-type="table-fn"}
   Female                    1.8 ± 0.3        1.6 ± 0.4[†](#t2n2){ref-type="table-fn"}          1.7 ± 0.4        1.8 ± 0.4
  LPS (EU/mL)                60 (44--80)      62 (49--82)                                       61 (44--79)      49 (40--55)[\*](#t2n1){ref-type="table-fn"}
  LPS/HDL ratio              37 (28--51)      45 (35--62)[\*](#t2n1){ref-type="table-fn"}       41 (30--54)      34 (26--43)[\*](#t2n1){ref-type="table-fn"}
  CRP (mg/L)                 0.7 (0.5--1.5)   1.2 (0.7--3.3)[†](#t2n2){ref-type="table-fn"}     0.9 (0.5--2.0)   1.7 (0.8--2.9)[\*](#t2n1){ref-type="table-fn"}
  Medication (%)                                                                                                 
   Lipid-lowering            1                0                                                 1                19[\*](#t2n1){ref-type="table-fn"}
   Antihypertensive          2                4                                                 3                56[\*](#t2n1){ref-type="table-fn"}
  Smoking (%)                14               21                                                16               15

Continuous values are presented as median (interquartile range) or as mean ± SD.

NDC-lean (BMI ≤ 25 kg/m^2^) and NDC-ow (BMI \>25 kg/m^2^) are compared with each other; NDC-all (NDC-lean + NDC-ow) and IgAGN groups are compared with each other.

\**P* ≤ 0.001,

†*P* ≤ 0.05.

TwinFat study {#s8}
-------------

NDC subjects of the TwinFat study were selected from two population-based prospective studies, FinnTwin16 (FT16) and FinnTwin12 (FT12), each consisting of five consecutive birth cohorts of Finnish twins ([@B17]). The participants were enrolled according to their responses to questions on weight and height in the last follow-up questionnaires at the age of 22 to 27 years, with the aim to cover the full BMI range of both normal-weight and obese subjects. The BMI range of the subjects participating in metabolic studies was 16.3 to 48.6 kg/m^2^. Among the 242 subjects, 92 twins (46 men and 46 women, 46 full pairs) were monozygotic (MZ) and 150 twins (86 men and 64 women, 75 full pairs) were same-sex dizygotic (DZ). To provide control subjects for unrelated individuals, one sibling was randomly selected from each twin pair for the current study. These were further divided into lean and overweight subjects by a BMI cutoff of 25 kg/m^2^ (see [[Data analysis and Statistical methods]{.smallcaps}](#s13){ref-type="sec"}).

All study protocols were approved by the local ethics committees and were in accordance with the Declaration of Helsinki. All study subjects gave their written informed consent to their participation in the study.

Laboratory analyses {#s9}
-------------------

Blood samples were drawn after an overnight fast. Nearly all of the biochemical analyses were performed in the Helsinki University Central Hospital Laboratory (HUSLAB; [www.hus.fi](http://www.hus.fi)) and in PSHP Laboratory Centre in Tampere ([www.laboratorio.fi](http://www.laboratorio.fi)), which are accredited hospital laboratories that belong to the Labquality Ltd. ([www.labquality.fi](http://www.labquality.fi)) national quality assessment program. Serum lipids were analyzed in three distinct laboratories: FinnDiane study (Central Laboratory, Division of Cardiology, Biomedicum, Helsinki), TwinFat study (HUSLAB), and the IgAGN study (PSHP Laboratory Centre). A set of 20 blood samples was sent to each laboratory for the assessment glucose, creatinine, cholesterol, triglycerides, and HDL cholesterol. All tested variables showed strong correlations between different laboratories (Spearman correlations *r* ≥0.96). Moreover, no significant differences were seen in analyte concentrations (data not shown). Insulin concentrations based on radioimmunoassay (LINCO Research Inc., St. Charles, MO) were transformed to match the insulin concentrations obtained with immunofluorometric assays (AutoDelfia, PerkinElmer, Beaconsfield, U.K.) ([@B18]).

FinnDiane study {#s10}
---------------

Fasting glucose values were measured from whole blood with a HemoCue device (HemoCue, Espoo, Finland). Plasma insulin was analyzed with the AutoDelfia immunofluorometric assay (PerkinElmer). High-sensitive C-reactive protein (hsCRP) was measured from serum by immunoprecipitation (Thermo Scientific, Vantaa, Finland). Serum lipid and lipoprotein concentrations were determined with a Cobas Mira analyzer using automated enzymatic methods (Hoffmann La Roche, Basel, Switzerland) in the Central Laboratory (Division of Cardiology, Biomedicum, Helsinki). Except for lipids, all other clinical measurements were performed in the HUSLAB. In type 1 diabetic patients, urinary MCP1 (uMCP1) was detected by ELISA according to the manufacturer's instructions (R&D Systems, Abingdon, U.K.). The uMCP1 protein levels were normalized with urinary creatinine concentrations (uCreat).

IgAGN study {#s11}
-----------

Serum insulin concentrations were determined using a human insulin--specific radioimmunoassay kit (Linco Research). Serum hsCRP values were analyzed using an immunoturbidimetric method with Cobas Integra 700 (provided by HoffmannLa Roche). Other laboratory variables were analyzed using the serum samples and spot and collection urine samples using in-house routine analytic methods in the laboratory of Tampere University Hospital (PSHP Laboratory Centre, Tampere).

TwinFat study {#s12}
-------------

Plasma glucose was measured using the spectrophotometric hexokinase and glucose-6-phosphate dehydrogenase assay (Gluko-quant glucose/hexokinase, Roche Diagnostics) with an automatic analyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan). Serum insulin concentrations were determined with the AutoDelfia immunofluorometric assay, and hsCRP with the particle-enhanced Cobas CRP-LatexHS immunoturbidimetric assay (Roche Diagnostics, Basel, Switzerland) on a Modular automatic analyzer. Concentrations of serum total cholesterol, HDL cholesterol, and triglyceride were measured with respective enzymatic kits from Roche Diagnostics using a Hitachi Modular autoanalyzer. All assays were performed in the HUSLAB.

The eGFR was determined by the Chronic Kidney Disease Epidemiology Collaboration equation ([@B16]). In type 1 diabetic patients, insulin sensitivity was determined using the equation for the estimated glucose disposal rate (eGDR) ([@B2]).

In the nondiabetic subjects, the homeostasis model assessment was used to calculate insulin resistance (HOMA-IR) index \[plasma insulin (μU/mL) × plasma glucose (mmol/L)/22.5\] ([@B19]). Before the HOMA calculations, blood glucose values were transformed to plasma values with a conversion factor (blood glucose × 1.12 = plasma glucose). The MetS was assessed according to the recent joint statement ([@B20]): central obesity (waist circumference ≥94 cm in men and ≥80 cm in women), triglycerides ≥1.7 mmol/L, HDL cholesterol \<1.0 mmol/L in men and \<1.30 mmol/L in women, blood pressure ≥130/85 mmHg, and fasting glucose ≥6.11 mmol/L. Three of five criteria are required for the diagnosis of MetS. All diabetic patients by definition fulfilled the criteria for high blood glucose.

In IgAGN patients, waist measurements were obtained from a baseline visit 6 years before the prospective visit, when blood samples were taken for the LPS analysis. The waist criterion was considered met only if BMI was unchanged or higher at the prospective visit.

Serum LPS activity was measured with the Limulus Amoebocyte Lysate chromogenic end-point assay (Hycult Biotechnology, Uden, the Netherlands; inter- and intra-assay coefficients of variation, 4.5%; sensitivity, 1.0 EU/mL). Because HDL cholesterol is the main factor involved in neutralization of endotoxemia, we used the LPS/HDL ratio as a functional measure of the LPS activity ([@B8],[@B9],[@B15]).

Data analysis and statistical methods {#s13}
-------------------------------------

In NDC subjects (FinnDiane control subjects + TwinFat individuals), interaction terms between MetS-associated variables and LPS activity were tested in a linear multivariate model. Because a significant interaction was found between BMI and LPS activity (data not shown), we subdivided 225 subjects from the FinnDiane and 118 from the TwinFat studies into two groups by a BMI cutoff of 25 kg/m^2^. Clinical characteristics of lean NDC (NDC-lean: BMI ≤25 kg/m^2^) and overweight NDC (NDC-ow: BMI \>25 kg/m^2^) subjects are presented in [Table 2](#T2){ref-type="table"}. The NDC-lean and the NDC-ow cohorts were combined into one larger cohort (NDC-all) for the evaluation of overall correlations between selected clinical variables ([Supplementary Appendix 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1)).

Normally distributed variables are presented as mean ± SD, whereas skewed variables are presented as median with IQR. Correlations between LPS-related variables and components of the MetS were evaluated with Pearson correlation analyses. To avoid the influence of HDL on the factors in the correlation analyses, residuals from the linear regression of LPS and HDL were calculated. Residuals or LPS alone were correlated to the MetS features to avoid the effect of HDL cholesterol. Statistical differences between groups were determined with the Student *t* test or the Mann-Whitney *U* test, when appropriate. Differences between multiple groups were analyzed by ANOVA or the Kruskal-Wallis test, depending on the distribution. The association between clinical variables and serum LPS activity was assessed with multivariate linear regression analyses. A value of *P* ≤ 0.05 was considered significant. All statistical analyses were done with SPSS 15.0 software (SPSS Inc., Chicago, IL).

RESULTS {#s14}
=======

The overall frequency of the MetS was 48% in type 1 diabetic patients. The MetS was more prevalent in diabetic patients with higher degree of albuminuria: macroalbuminuria (70%), microalbuminuria (47%), and normal AER (43%). Type 1 diabetic patients with macroalbuminuria had a significantly higher LPS/HDL ratio (50 \[34--77\] EU/mL; *P* \< 0.001) compared with diabetic patients with microalbuminuria (37 \[29--50\] EU/mL) or normal AER (35 \[27--52\] EU/mL; [Table 1](#T1){ref-type="table"}). Of all tested variables, serum LPS activity showed the strongest correlation with serum triglyceride concentrations (all type 1 diabetic patients, *r* = 0.73, *P* \< 0.001).

In type 1 diabetic patients with normal AER, serum LPS activity was assessed by number of individual components of the MetS (scores 1--5). Because of the low number of patients, those who had four or five scores were pooled into one group. A concomitant rise in the serum LPS activity and the metabolic score was observed: one score, 54 (48--62); two scores, 55 (49--63); three scores, 57 (51--70); and four and five scores, 78 (62--94). High blood pressure was the most frequent component of the MetS, followed by increased waist circumference, low HDL cholesterol, and high triglycerides ([Supplementary Appendix 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1)).

Type 1 diabetic patients with normal AER were divided into quartiles according to their LPS/HDL ratio. The 147 patients in the highest quartile (quartile 4) were significantly younger and had developed diabetes at an earlier age compared with the 145 patients in the lowest quartile (quartile 1). The quartile 4 subjects also had significantly higher HbA~1c~, BMI, waist circumference, serum triglycerides, apolipoprotein B (apoB), and diastolic blood pressure than subjects in quartile 1. Insulin sensitivity, measured with eGDR, decreased with increasing LPS/HDL ratio. The percentage of diabetic patients who fulfilled the MetS criteria was significantly higher in quartile 4 than in quartile 1. The eGFR and the uMCP1/uCreat ratio were also significantly higher in quartile 4 than in quartile 1 ([Table 3](#T3){ref-type="table"}). In diabetic patients, the overall correlation between LPS/HDL-ratio and uMCP1/uCreat was *r* = 0.21 (*P* \< 0.001).

###### 

LPS/HDL quartiles in type 1 diabetic patients with normal albumin excretion

                                       LPS/HDL quartiles                                                                                                    
  ------------------------------------ ------------------- ----------------------------------------------- ------------------------------------------------ ------------------------------------------------
  *N* (male/female)                    145 (34/111)        148 (61/87)                                     147 (79/68)                                      147 (83/64)
  Age (years)                          48 (40--57)         47 (39--54)                                     44 (36--55)[†](#t3n2){ref-type="table-fn"}       39 (31--47)[\*](#t3n1){ref-type="table-fn"}
  Age at onset (years)                 19 (11--28)         16 (10--25)                                     17 (10--26)                                      13 (9--21)[\*](#t3n1){ref-type="table-fn"}
  Duration of diabetes (years)         29 ± 13             29 ± 12                                         27 ± 13                                          25 ± 10[†](#t3n2){ref-type="table-fn"}
  HbA~1c~ (%)                          7.3 ± 1.6           7.6 ± 1.2                                       7.7 ± 1.2[†](#t3n2){ref-type="table-fn"}         7.9 ± 0.9[\*](#t3n1){ref-type="table-fn"}
  BMI (kg/m^2^)                        24.4 ± 3.0          25.5 ± 3.5[†](#t3n2){ref-type="table-fn"}       25.7 ± 4.0[†](#t3n2){ref-type="table-fn"}        26.9 ± 5.5[\*](#t3n1){ref-type="table-fn"}
  Waist (cm)                                                                                                                                                
   Male                                89 ± 9              92 ± 10                                         93 ± 10                                          96 ± 11[†](#t3n2){ref-type="table-fn"}
   Female                              80 ± 9              83 ± 10[†](#t3n2){ref-type="table-fn"}          83 ± 11[†](#t3n2){ref-type="table-fn"}           90 ± 13[\*](#t3n1){ref-type="table-fn"}
  Blood pressure (mmHg)                                                                                                                                     
   Systolic                            137 ± 20            136 ± 17                                        137 ± 17                                         135 ± 15
   Diastolic                           76 ± 10             77 ± 8                                          78 ± 9                                           81 ± 9[\*](#t3n1){ref-type="table-fn"}
  eGDR (mg/kg/min)                     7.4 ± 2.3           7.0 ± 2.3                                       6.4 ± 2.3[\*](#t3n1){ref-type="table-fn"}        6.1 ± 2.3[\*](#t3n1){ref-type="table-fn"}
  Cholesterol (mmol/L)                 4.7 ± 0.7           4.6 ± 0.7                                       4.6 ± 0.8                                        4.8 ± 0.9
  Triglycerides (mmol/L)               0.7 (0.6--0.8)      0.8 (0.7--0.9)[†](#t3n2){ref-type="table-fn"}   1.0 (0.8--1.2)[\*](#t3n1){ref-type="table-fn"}   1.4 (1.2--1.8)[\*](#t3n1){ref-type="table-fn"}
  HDL cholesterol (mmol/L)                                                                                                                                  
   Male                                2.1 ± 0.5           1.6 ± 0.2[\*](#t3n1){ref-type="table-fn"}       1.4 ± 0.2[\*](#t3n1){ref-type="table-fn"}        1.1 ± 0.2[\*](#t3n1){ref-type="table-fn"}
   Female                              2.0 ± 0.4           1.7 ± 0.2[\*](#t3n1){ref-type="table-fn"}       1.5 ± 0.3[\*](#t3n1){ref-type="table-fn"}        1.4 ± 0.3[\*](#t3n1){ref-type="table-fn"}
  apoA1 (mg/dL)                        161 ± 33            145 ± 31[\*](#t3n1){ref-type="table-fn"}        142 ± 29[\*](#t3n1){ref-type="table-fn"}         136 ± 29[\*](#t3n1){ref-type="table-fn"}
  apoB (mg/dL)                         64 ± 14             70 ± 13[\*](#t3n1){ref-type="table-fn"}         77 ± 16[\*](#t3n1){ref-type="table-fn"}          88 ± 22[\*](#t3n1){ref-type="table-fn"}
  Nonesterified fatty acids (mmol/L)   227 (134--455)      191 (123--378)                                  200 (128--328)                                   240 (167--385)
  CRP (mg/L)                           0.7 (0.3--1.6)      0.7 (0.3--1.4)                                  1.0 (0.4--2.1)                                   1.2 (0.4--3.5)[†](#t3n2){ref-type="table-fn"}
  Serum creatinine (µmol/L)                                                                                                                                 
   Male                                72 ± 12             77 ± 12                                         78 ± 13                                          76 ± 11
   Female                              67 ± 11             64 ± 10                                         64 ± 12                                          68 ± 12
  eGFR (mL/min/1.73 m^2^)              97 (84--108)        100 (92--109)[†](#t3n2){ref-type="table-fn"}    103 (93--115)[†](#t3n2){ref-type="table-fn"}     106 (93--115)[\*](#t3n1){ref-type="table-fn"}
  uMCP1/uCreat (pg/mL/µmol/L)          13 (8--23)          14 (9--23)                                      15 (9--25)                                       16 (10--30)[†](#t3n2){ref-type="table-fn"}
  Metabolic syndrome (%)               22                  38[†](#t3n2){ref-type="table-fn"}               42[\*](#t3n1){ref-type="table-fn"}               69[\*](#t3n1){ref-type="table-fn"}
  Medication                                                                                                                                                
   Antihypertension (%)                35                  26                                              33                                               32
   Lipid-lowering (%)                  23                  16                                              21                                               26
  Smoking (%)                          10                  13                                              18[†](#t3n2){ref-type="table-fn"}                25[†](#t3n2){ref-type="table-fn"}

Continuous values are presented as median (interquartile range) or mean ± SD.

All values compared with quartile 1.

\**P* ≤ 0.001,

†*P* ≤ 0.05.

These results did not change if diabetic patients were subdivided into quartiles by LPS activity instead of by the LPS/HDL ratio (data not shown). The association between clinical outcomes and serum LPS activity was assessed with multivariate linear regression analyses. In diabetic patients with normal AER, the variables with the strongest association with serum LPS activity were serum triglycerides (β = 0.69, *P* \< 0.001), age at onset of diabetes (β = −0.14, *P* \< 0.001), diastolic blood pressure (β = 0.10, *P* = 0.004), and uMCP1/creatinine ratio (β = 0.10, *P* = 0.003). Clinical variables significantly associated in the univariate model (HbA~1c~, HDL cholesterol, and waist circumference) were not significant in the multivariate analysis. Similar results were obtained if the variables were added into the model by the backward elimination method (data not shown).

The overall prevalence of the MetS was much lower in the nondiabetic cohorts than in the type 1 diabetic patients: IgAGN (15%), NDC-ow (15%), and NDC-lean (2%). The NDC-ow group had significantly higher serum LPS/HDL ratios than the NDC-lean or the IgAGN cohorts ([Table 2](#T2){ref-type="table"}). The subjects in the NDC-ow group had also higher systolic blood pressure, fasting insulin, serum cholesterol, and serum CRP than subjects in the NDC-lean group. Correlations between serum endotoxin levels (LPS/HDL ratio, LPS, and LPS-HDL correlation residual) and individual components of the MetS are shown in [Supplementary Appendix 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1). In nondiabetic patients, the most significant variable associated with the serum LPS/HDL ratio was serum triglycerides (NDC-all, *r* = 0.51; IgAGN, *r* = 0.50). Regardless of the analysis mode the results remained comparable. Notably, correlations of individual MetS components were stronger overall in the NDC-ow than in the NDC-lean group. Effects of BMI and fasting insulin on serum LPS activity were explored in the nondiabetic cohorts. Subjects in the NDC-all were divided into eight groups based on a BMI cutoff of 25 kg/m^2^ and quartiles of fasting insulin. As seen in [Supplementary Appendix 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1), BMI and insulin had a synergistic effect on the LPS/HDL ratio.

Of note, neither measurements of kidney function nor the amount of proteinuria was associated with serum LPS activity in the IgAGN cohort (data not shown). Although patients with IgAGN and diabetic patients with macroalbuminuria had a similar BMI (26.5 ± 4.3 vs. 27.0 ± 4.9 kg/m^2^; *P* = 0.34), the LPS/HDL ratio was significantly higher in the diabetic group (35 \[26--43\] vs. 50 \[34--77\] EU/mL; *P* \< 0.001). The high LPS/HDL ratio could not be entirely explained by impaired kidney function, because these results remained similar when the IgAGN subjects and the patients with type 1 diabetes were matched for sex and eGFR (data not shown). Of note, the differences between the groups were more pronounced in patients with higher triglyceride concentrations ([Supplementary Appendix 4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1)).

CONCLUSIONS {#s15}
===========

The current study demonstrates that serum LPS activity strongly correlates with MetS-associated features. The association of serum LPS activity with the components of the MetS is in line with results obtained from FINRISK97, a large Finnish population-based study that also demonstrated that endotoxemia is an independent risk factor for incident diabetes ([@B21]). High serum LPS activity combined with metabolic abnormalities may thus pose a potent risk for the later development of micro- and macrovascular complications and offer a new tool to estimate the metabolic risk profile in other populations as well.

Dyslipidemia is a well-recognized risk factor for the development of macrovascular complications in type 1 diabetic patients. Lipid abnormalities may also increase the risk for microvascular complications (e.g., diabetic retinopathy and nephropathy) ([@B22]). Hypertriglyceridemia is a prognostic marker for declining kidney function in IgAGN patients ([@B5]) and is also a risk marker for coronary heart disease in these patients ([@B3]). In the current study, most diabetic patients with high serum LPS activity had elevated serum triglycerides and low HDL-cholesterol concentrations. Of all the tested clinical variables, the strongest correlation was observed between the LPS/HDL ratio and serum triglyceride concentrations. High fasting concentrations of triglycerides predict postprandial hypertriglyceridemia and the development of insulin resistance ([@B23]).

Serum LPS activity correlated positively with serum apoB concentrations, which suggests that endotoxins are most likely transported by VLDL, LDL, or chylomicron particles. Most of the circulating endotoxins are generally believed to originate from bacteria colonizing the gut and provide a large reservoir of LPS molecules ([@B24]). Human and animal studies have both highlighted the importance of the composition of the diet for its influence on the endotoxin absorption process. Consumption of an energy-rich high-fat diet may result in increased levels of gut-derived bacterial endotoxins in circulation. Moreover, obesity-related changes in the gut microflora have been reported both in mice and humans. Alterations in the bacterial composition of the gut may also result in significant changes in the metabolic nutrient harvest ([@B10],[@B11]). We note that a positive correlation was observed between the LPS/HDL ratio and obesity-related variables in all study groups. Could high serum LPS activity levels in type 1 diabetic patients be explained by gut-related factors other than diet? In addition to the dietary habits, administration of antimicrobial agents may disrupt the normal composition of the gut microbiota. Bacterial overgrowth may also result in intestinal dysmotility in diabetic patients. Diabetes itself may also induce ultrastructural changes in the mucosal barrier of the gut, which in turn may lead to increased permeability of the intestine.

Insulin resistance combined with obesity increases the risk for type 2 diabetes and cardiovascular disease ([@B20]). Notably, insulin resistance has also been strongly linked to the development of kidney dysfunction in patients with type 1 diabetes ([@B2]). Kidney patients may already be insulin-resistant before the onset of kidney failure ([@B25]). In vivo experiments have demonstrated that injections of bacterial endotoxins induce systemic inflammation, which is accompanied by the appearance of insulin resistance ([@B12]). In the current study, we showed that serum LPS activity is inversely correlated with insulin sensitivity both in diabetic and nondiabetic cohorts.

Elevated serum levels of inflammatory markers, such as tumor necrosis factor-α, interleukin-6, and CRP, are common in obesity and diabetes-related diseases ([@B6]). We have shown that serum levels of these markers are increased in type 1 diabetic patients with kidney disease ([@B1]). In the current study, serum LPS activity correlated positively with CRP in the three study cohorts, which suggests that the "low-grade inflammation" is explained to some extent by exposure to structural components of the gram-negative bacteria. LPS induces the expression of the MCP1 chemokine, which recruits and activates monocytes from the circulation to the site of inflammation.

Notably, previous studies have implicated a potential role for MCP1 in kidney-related diseases ([@B13],[@B14]). We have previously shown that serum LPS activity increases along with declining kidney function ([@B15]). In the current study, the urinary MCP1/creatinine ratio increased in parallel with the serum LPS activity in diabetic patients with normal AER, which could indicate that the LPS-stimulated MCP1 excretion may be an early marker for kidney disease progression. Type 1 diabetic patients with kidney dysfunction had significantly higher levels of serum LPS activity and displayed more often pathologic features of the MetS than patients with IgAGN. This would indicate that diabetic patients are more susceptible to metabolic endotoxemia than patients with IgAGN.

Taken together, these data show that endotoxins derived from gram-negative bacteria are strongly associated with the MetS variables in vivo. These observations may have clinical implications, because high LPS activity is more often found in subjects who show signs of dyslipidemia, insulin resistance, overweight, and inflammation---factors that increase the risk for diverse micro- and macrovascular complications.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1>.

\*A complete list of participating centers in the FinnDiane Collection can be found in the [Supplementary Data](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2197/-/DC1).
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